STANDARD BIOTOOLS INC. shareholders approved Approval of the Amendment to the Amended and Restated 2017 Employee Stock Purchase Plan at the 2026-04-24 meeting.
“Approval of the Amendment to the Amended and Restated 2017 Employee Stock Purchase Plan. The proposal to approve the amendment to the ESPP to increase the shares of common stock reserved thereunder by 1,200,000 shares was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 237,474,844 12,276,507 30,247 86,119,046”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved Approval of the 2026 Equity Incentive Plan at the 2026-04-24 meeting.
“Approval of the 2026 Equity Incentive Plan. The proposal to approve the 2026 Plan was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 228,342,854 17,821,911 3,616,833 86,119,046”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-04-24 meeting.
“Ratification of Appointment of Independent Registered Public Accounting Firm. The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was approved by the following vote: Votes For Votes Against Abstentions 330,172,606 652,236 5,075,802”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved Advisory Vote on Approval of Executive Compensation at the 2026-04-24 meeting.
“Advisory Vote on Approval of Executive Compensation. The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2025 was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 209,778,412 36,318,595 3,684,591 86,119,046”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved Election of Class I Directors at the 2026-04-24 meeting.
“Election of Class I Directors. The following nominees were elected to serve as Class I directors, to hold office until the Company’s 2029 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified or their earlier resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Michael Egholm, Ph.D. 236,313,971 13,467,627 86,119,046 Thomas Carey 227,843,498 21,938,100 86,119,046 Eli Casdin 234,717,465 15,064,133 86,119,046”
Material Agreements
STANDARD BIOTOOLS INC. entered into Agreement and Plan of Merger and Reorganization with Treeline Biosciences, Inc. (effective 2026-06-06).
“Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Treeline Biosciences, Inc., a Delaware corporation (“Treeline”), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Standard BioTools (“Merger Sub”)”
Earnings Releases
STANDARD BIOTOOLS INC. reported the quarter ended March 31, 2026 results: revenue $21.1 million, net income $14.6 million. Guidance reaffirmed.
“(NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026. Recent Highlights: • First quarter 2026 revenue of $21.1 million • 54% reduction in operating loss and 78% improvement in adjusted EBITDA year-over-year supporting path to positive adjusted EBITDA exiting 2026 • $524 million in cash &”
Listing & Compliance Notices
STANDARD BIOTOOLS INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“April 20, 2026, Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) in”
M&A Transactions
STANDARD BIOTOOLS INC. completed a disposition involving Illumina, Inc. for $350 million in upfront cash and up to $75 million in earnout payments for aggregate cash consideration of up to $425 million (closed 2026-01-30).
“which are being retained by the Company. Under the terms of the Purchase Agreement, Purchaser acquired the Shares for aggregate cash consideration of up to $425 million, comprising (i) an upfront payment of $350 million in cash, which was paid at the closing of the Transaction, as adjusted in accordance with the terms of the Purchase Agreement”
Restructurings & Charges
STANDARD BIOTOOLS INC. announced a restructuring with charges of approximately $7.5 million (approximately 15% of its total global workforce).
“The Company currently expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be approximately $7.5 million. These estimates are subject to a number of assumptions, and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that”
Restructurings & Charges
STANDARD BIOTOOLS INC. announced a restructuring with charges of approximately $3.6 million affecting R&D function (reduction-in-force of certain U.S. employees in the Company’s R&D function, including members of its management team).
“The Company currently expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be approximately $3.6 million, which includes approximately $0.9 million of non-cash expenses related to vesting of share-based awards. These estimates are subject to a number of assumptions, and actual”
Jeremy Davis departed as Chief Commercial Officer at STANDARD BIOTOOLS INC..
“On January 3, 2025, Standard BioTools Inc. (the “Company”) and Jeremy Davis, the Company’s Chief Commercial Officer, mutually determined that Mr. Davis will no longer serve in such position, effective as of February 1, 2025.”
Alex Kim was appointed as Chief Financial Officer at STANDARD BIOTOOLS INC..
“On November 6, 2024, the Board of Directors of Standard BioTools Inc. (the “Company”) appointed Alex Kim, who has been serving as the Company’s Interim Chief Financial Officer since September 1, 2024, as the Company’s fulltime Chief Financial Officer, effective as of November 11, 2024 (the “Effective Date”).”
Alex Kim was appointed as Interim Chief Financial Officer at STANDARD BIOTOOLS INC..
“On July 30, 2024, the Company’s Board of Directors appointed Alex Kim, the Company’s Chief Operating Officer, to serve as Interim Chief Financial Officer of the Company, starting on September 1, 2024, to succeed Mr. Black while the Company searches for a permanent Chief Financial Officer.”
Jeffrey Black resigned as Senior Vice President and Chief Financial Officer at STANDARD BIOTOOLS INC..
“On July 26, 2024, Jeffrey Black resigned as the Senior Vice President and Chief Financial Officer (serving as the principal financial and accounting officer) of Standard BioTools Inc. (the “Company”), effective as of August 31, 2024.”
Earnings Releases
STANDARD BIOTOOLS INC. reported the three months ended March 31, 2024 results: revenue $45.5 million, net income $(32.2) million. Guidance reaffirmed.
“On May 8, 2024, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months ended March 31, 2024.”
Restructurings & Charges
STANDARD BIOTOOLS INC. announced a restructuring with charges of Streamlined Operational Expenditures including closure of the Company's R&D facility in San Diego, reductions in SG&A expenses, and savings related to a more pr affecting R&D facility in San Diego and overall SG&A expenses.
“Streamlined Operational Expenditures: Includes reductions in overall selling, general and administrative (SG&A) expenses, the closure of the Company’s R&D facility in San Diego, as well as savings related to a more prioritized R&D strategy.”
Restructurings & Charges
STANDARD BIOTOOLS INC. announced a restructuring with charges of Reduction-in-force of approximately 10% of total workforce, including elimination of certain senior management positions, with expected expenses of $10 million affecting total workforce (approximately 10% of its total workforce).
“On April 25, 2024, Standard BioTools Inc. (the “Company”) announced a reduction-in-force of approximately 10% of its total workforce, including the elimination of certain senior management positions following the closing of the Company’s merger with SomaLogic, Inc., as part of an operational restructuring plan.”
Governance Changes
STANDARD BIOTOOLS INC.: Eliminated Series B Preferred Stock designations from the Certificate of Incorporation via Certificates of Elimination (effective 2024-03-18).
“On March 18, 2024, following the closing of the Exchange, the Company filed a Certificate of Elimination of Series B-1 Convertible Preferred Stock and a Certificate of Elimination of Series B-2 Convertible Preferred Stock (together, the “Certificates of Elimination”) with the Secretary of State of the State of Delaware.”
Material Agreements
STANDARD BIOTOOLS INC. entered into Exchange Agreement with Casdin Private Growth Equity Fund II, L.P., Casdin Partners Master Fund, L.P., Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP (effective 2024-03-18).
“On March 18, 2024, Standard BioTools Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with Casdin Private Growth Equity Fund II, L.P., Casdin Partners Master Fund, L.P., Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP (each, an “Investor” and, collectively, the “Investors”).”
Earnings Releases
STANDARD BIOTOOLS INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $28.2, net income $(19.8).
“2023 Fourth Quarter and Full Year Selected Financial Results 2 Quarter Ended Year Ended (Unaudited, in millions, except percentages) December 31, 2023 December 31, 2023 Revenue $ 28.2 $ 106.3 GAAP gross margin 47.4 % 47.4 % Non-GAAP gross margin 59.6 % 60.1 % Operating expenses $ 34.7 $ 127.1 Non-GAAP operating expenses $ 24.3 $ 98.6 Operating loss $ (21.4 ) $”
Earnings Releases
STANDARD BIOTOOLS INC. reported full year 2023 results: revenue approximately $106 million.
“full year 2023 revenue of approximately $106 million”
Earnings Releases
STANDARD BIOTOOLS INC. reported fourth quarter 2023 results: revenue approximately $28 million.
“Standard BioTools expects fourth quarter 2023 revenue of approximately $28 million”
Governance Changes
STANDARD BIOTOOLS INC.: Increased authorized common stock from 400,000,000 shares to 600,000,000 shares (effective 2024-01-04).
“On January 4, 2024, the Company filed a Certificate of Amendment to its Eighth Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to increase the total number of shares of Standard BioTools Common Stock authorized for issuance thereunder from 400,000,000 shares to 600,000,000 shares (the “Charter Amendment”).”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved To approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Standard BioTools Share Issuance Proposal and the Standard BioTools Charter Amendment Proposal if there are insufficient votes at the time of such adjournment at the 2024-01-04 meeting.
“Proposal 5. To approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Standard BioTools Share Issuance Proposal and the Standard BioTools Charter Amendment Proposal if there are insufficient votes at the time of such adjournment to approve such proposals. Votes For Votes Against Abstentions Broker Non-Votes 124,087,718 6,753,379 212,522 None”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved To approve the A&R 2011 Plan Amendment. at the 2024-01-04 meeting.
“Proposal 4. To approve the A&R 2011 Plan Amendment. Votes For Votes Against Abstentions Broker Non-Votes 119,362,194 11,536,749 154,676 None”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools’ named executive officers and to SomaLogic’s Chief Executive Officer that is based on or otherwise relates to the Merger. at the 2024-01-04 meeting.
“Proposal 3. To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools’ named executive officers and to SomaLogic’s Chief Executive Officer that is based on or otherwise relates to the Merger. Votes For Votes Against Abstentions Broker Non-Votes 119,441,699 11,267,991 343,929 None”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved To approve the Charter Amendment (the 'Standard BioTools Charter Amendment Proposal'). at the 2024-01-04 meeting.
“Proposal 2. To approve the Charter Amendment (the “Standard BioTools Charter Amendment Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 125,698,245 5,230,711 124,663 None”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved To approve the issuance of shares of Standard BioTools Common Stock in connection with the Merger and in accordance with Nasdaq Listing Rule 5635(a) (the 'Standard BioTools Share Issuance Proposal'). at the 2024-01-04 meeting.
“Proposal 1. To approve the issuance of shares of Standard BioTools Common Stock in connection with the Merger and in accordance with Nasdaq Listing Rule 5635(a) (the “Standard BioTools Share Issuance Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 125,739,416 5,186,617 127,586 None”
M&A Transactions
STANDARD BIOTOOLS INC. completed an acquisition involving SomaLogic, Inc. for 1.11 shares of Standard BioTools common stock per share (closed 2024-01-05).
“of the Merger, each issued and outstanding share of common stock of SomaLogic, par value $0.0001 per share (“SomaLogic Common Stock”), was converted into the right to receive 1.11 (the “Exchange Ratio”) shares of common stock of Standard BioTools, par value $0.001 per share (“Standard BioTools Common Stock”), and cash in lieu of fractional shares.”
Martin Madaus resigned as Director at STANDARD BIOTOOLS INC..
“Carlos Paya, M.D., Ph.D., Laura Clague and Martin Madaus, Ph.D. resigned from Standard BioTools’ board of directors”
Laura Clague resigned as Director at STANDARD BIOTOOLS INC..
“Carlos Paya, M.D., Ph.D., Laura Clague and Martin Madaus, Ph.D. resigned from Standard BioTools’ board of directors”
Carlos Paya resigned as Director at STANDARD BIOTOOLS INC..
“Carlos Paya, M.D., Ph.D., Laura Clague and Martin Madaus, Ph.D. resigned from Standard BioTools’ board of directors”
Material Agreements
STANDARD BIOTOOLS INC. entered into Agreement and Plan of Merger with SomaLogic, Inc. (effective 2023-10-04).
“On October 4, 2023, Standard BioTools Inc., a Delaware corporation (“Standard BioTools” or the “Company”), SomaLogic, Inc., a Delaware corporation (“SomaLogic”), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”)”
Earnings Releases
STANDARD BIOTOOLS INC. reported quarter ended June 30, 2023 results: revenue $27.7, net income ($17.0).
“Selected Financial Results (Numbers in millions, except percentages) Quarter Ended June 30, 2023 Quarter Ended June 30, 2022 Revenue $27.7 $18.8 (a) Gross margin 49.2% 23.6% Non-GAAP gross margin 60.9% 40.2% Operating expenses $31.1 $43.0 Non-GAAP operating expenses $25.2 $33.8 Operating loss ($17.4) ($38.6) Net loss ($17.0) ($63.5)”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved Election of B-2 Director (Series B-2 Preferred Stock).
“The holders of Series B-2 Preferred Stock, voting separately as a class, voted all shares of Series B-2 Preferred Stock to nominate and elect Martin D. Madaus to the Company’s board of directors in connection with the Annual Meeting. Nominee Votes For Votes Withheld Martin D. Madaus 127,779 -”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved Election of B-1 Director (Series B-1 Preferred Stock).
“The holders of Series B-1 Preferred Stock, voting separately as a class, voted all shares of Series B-1 Preferred Stock to nominate and elect Eli Casdin to the Company’s board of directors in connection with the Annual Meeting. Nominee Votes For Votes Withheld Eli Casdin 127,780 -”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-12-31 meeting.
“The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 was approved by the following vote: Votes For Votes Against Abstentions 139,270,633 233,343 32,683”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved Approval of the Amended and Restated 2011 Equity Incentive Plan.
“The proposal to approve the Company’s Amended and Restated 2011 Equity Incentive Plan to increase the shares of common stock reserved thereunder by 4,700,000 shares was approved by the following vote: Votes For Votes Against Abstentions Broker Non-Votes 109,601,367 11,404,808 458,590 18,071,894”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved Advisory Vote on Frequency of Vote to Approve Executive Compensation (one year).
“The proposal to approve, on an advisory basis, the frequency of the advisory stockholder vote on the compensation of the Company’s named executive officers was ratified as one year by the following vote: Votes For One Year Votes For Two Years Votes For Three Years Abstentions Broker Non-Votes 120,966,667 163,420 221,890 112,788 18,071,894”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved Advisory Vote on Approval of Executive Compensation at the 2022-12-31 meeting.
“The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2022 was approved by the following vote: Votes For Votes Against Abstentions Broker Non-Votes 99,659,482 21,330,720 474,563 18,071,894”
Shareholder Votes
STANDARD BIOTOOLS INC. shareholders approved Election of Class I Directors.
“The following nominees were elected to serve as Class I directors, to hold office until the Company’s 2026 annual meeting of stockholders or until their respective successors have been duly elected and qualified or their earlier resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Michael Egholm, Ph.D. 120,101,799 1,362,966 18,071,894 Fenel M. Eloi 120,414,232 1,050,533 18,071,894”
Jeffrey G. Black was appointed as Chief Financial Officer at STANDARD BIOTOOLS INC..
“On May 15, 2023, Standard BioTools Inc. (the “Company”) announced the appointment of Jeffrey G. Black, age 54, as Chief Financial Officer of the Company, effective as of May 15, 2023.”
Earnings Releases
STANDARD BIOTOOLS INC. reported first quarter ended March 31, 2023 results: revenue $25.1 million.
“in the fourth quarter and a 46% reduction from the $15.6 in the first quarter last year GAAP revenue (includes discontinued/COVID-19 products) decreased 5.2% year-over-year to $25.1 million, with a 1.8% year-over-year increase in ongoing, core product and service revenue to $24.3 million GAAP product and services margin of 46.6%, an improvement of 567 basis points”
Gerhard Burbach departed as member of the board of directors at STANDARD BIOTOOLS INC..
“On April 28, 2023, Gerhard Burbach, a member of the board of directors (the “Board”) of Standard BioTools Inc. (the “Company”), notified the Board of his intent to retire from the Board and the nominating and corporate governance committee and compensation committee of the Board, effective immediately following the Company’s 2023 annual meeting of stockholders on June 14, 2023.”
Fenel Eloi was appointed as Class I director at STANDARD BIOTOOLS INC..
“On March 15, 2023, upon the recommendation of the nominating and corporate governance committee of the Board, the Board appointed Fenel Eloi to fill the Board vacancy created by Mr. Colston’s resignation.”
Bill W. Colston resigned as Member of the Board of Directors at STANDARD BIOTOOLS INC..
“On March 15, 2023, Bill W. Colston, a member of the board of directors (the “Board”) of Standard BioTools Inc. (the “Company”), notified the Board of his intent to resign from the Board and the compensation committee of the Board, effective March 15, 2023.”
Earnings Releases
STANDARD BIOTOOLS INC. updated its 2023 guidance (initiated).
“For 2023, Standard BioTools expects flat-to-moderate growth in core product and service revenues relative to 2022 core product and service revenues of $94.5 million.”
Earnings Releases
STANDARD BIOTOOLS INC. reported the fiscal year ended December 31, 2022 results: revenue $97.9 million. Guidance reaffirmed.
“GAAP revenues were $97.9 million compared to $130.6 million in 2021.”
Earnings Releases
STANDARD BIOTOOLS INC. reported the three months ended December 31, 2022 results: revenue $27.0 million. Guidance reaffirmed.
“Fourth quarter 2022 GAAP revenues were $27.0 million.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.